Stroke drug combo aims to boost recovery

NCT ID NCT06949228

Recruiting now Disease control Sponsor: ProMedica Health System Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving the clot-busting drug tenecteplase directly into the brain artery after mechanical clot removal can improve outcomes for people with acute ischemic stroke. About 132 adults aged 18-85 with large vessel blockages will be randomly assigned to receive the drug or standard care. The goal is to see if the drug helps more patients recover with little or no disability at 90 days, while monitoring for brain bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tenecteplase
What this could lead to: If it works, this could improve recovery and reduce disability after a severe stroke by clearing remaining clots.
What could go wrong: This is an early combined Phase 2/3 trial with only 132 participants, so results may not apply to all stroke patients. There is a risk of brain bleeding from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute disease ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE DISEASE ISCHEMIC STROKE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

ProMedica Toledo Hospital
RECRUITING

Toledo, Ohio, 43606, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.